Abstract
This cross-sectional cost analysis uses data from the 2018 Health and Retirement Study to estimate the potential future Medicare spending and beneficiary costs for lecanemab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
